
Alexander Burashnikov

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5840376/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The M Cell: Journal of Cardiovascular Electrophysiology, 1999, 10, 1124-1152.	1.7	525
2	Atrium-Selective Sodium Channel Block as a Strategy for Suppression of Atrial Fibrillation. Circulation, 2007, 116, 1449-1457.	1.6	390
3	Reinduction of Atrial Fibrillation Immediately After Termination of the Arrhythmia Is Mediated by Late Phase 3 Early Afterdepolarization–Induced Triggered Activity. Circulation, 2003, 107, 2355-2360.	1.6	291
4	Synergistic Effect of the Combination of Ranolazine and Dronedarone to Suppress Atrial Fibrillation. Journal of the American College of Cardiology, 2010, 56, 1216-1224.	2.8	123
5	Late-Phase 3 EAD. A Unique Mechanism Contributing to Initiation of Atrial Fibrillation. PACE - Pacing and Clinical Electrophysiology, 2006, 29, 290-295.	1.2	117
6	Atrial-selective inhibition of sodium-channel current by Wenxin Keli is effective in suppressing atrial fibrillation. Heart Rhythm, 2012, 9, 125-131.	0.7	75
7	Transmembrane action potential heterogeneity in the canine isolated arterially perfused right atrium: effect of IKr and IKur/Ito block. American Journal of Physiology - Heart and Circulatory Physiology, 2004, 286, H2393-H2400.	3.2	63
8	Atrial-selective effects of chronic amiodarone in the management of atrial fibrillation. Heart Rhythm, 2008, 5, 1735-1742.	0.7	63
9	New developments in atrial antiarrhythmic drug therapy. Nature Reviews Cardiology, 2010, 7, 139-148.	13.7	61
10	<i>Atrial‣elective Sodium Channel Block as a Strategy for Suppression of Atrial Fibrillation</i> . Annals of the New York Academy of Sciences, 2008, 1123, 105-112.	3.8	53
11	Prominent IKs in Epicardium and Endocardium Contributes to Development of Transmural Dispersion of Repolarization but Protects Against Development of Early Afterdepolarizations. Journal of Cardiovascular Electrophysiology, 2002, 13, 172-177.	1.7	52
12	Atrial-Selective Sodium Channel Block Strategy to Suppress Atrial Fibrillation: Ranolazine versus Propafenone. Journal of Pharmacology and Experimental Therapeutics, 2012, 340, 161-168.	2.5	49
13	Can inhibition of IKur promote atrial fibrillation?. Heart Rhythm, 2008, 5, 1304-1309.	0.7	48
14	Atrial-Selective Sodium Channel Blockers: Do They Exist?. Journal of Cardiovascular Pharmacology, 2008, 52, 121-128.	1.9	46
15	Rate-Dependent Effects of Vernakalant in the Isolated Non-Remodeled Canine Left Atria Are Primarily Due to Block of the Sodium Channel. Circulation: Arrhythmia and Electrophysiology, 2012, 5, 400-408.	4.8	46
16	Role of Late Sodium Channel Current Block in the Management of Atrial Fibrillation. Cardiovascular Drugs and Therapy, 2013, 27, 79-89.	2.6	46
17	Fever Accentuates Transmural Dispersion of Repolarization and Facilitates Development of Early Afterdepolarizations and Torsade de Pointes Under Long-QT Conditions. Circulation: Arrhythmia and Electrophysiology, 2008, 1, 202-208.	4.8	40
18	Acute dronedarone is inferior to amiodarone in terminating and preventing atrial fibrillation in canine atria. Heart Rhythm, 2010, 7, 1273-1279.	0.7	29

#	Article	IF	CITATIONS
19	Novel pharmacological targets for the rhythm control management of atrial fibrillation. , 2011, 132, 300-313.		29
20	Differences in the electrophysiologic response of four canine ventricular cell types to α1-adrenergic agonists. Cardiovascular Research, 1999, 43, 901-908.	3.8	28
21	AZD1305 Exerts Atrial Predominant Electrophysiological Actions and Is Effective in Suppressing Atrial Fibrillation and Preventing Its Reinduction in the Dog. Journal of Cardiovascular Pharmacology, 2010, 56, 80-90.	1.9	25
22	Mechanisms underlying atrial-selective block of sodium channels by Wenxin Keli: Experimental and theoretical analysis. International Journal of Cardiology, 2016, 207, 326-334.	1.7	23
23	Atrial-selective Prolongation of Refractory Period With AVE0118 is Due Principally to Inhibition of Sodium Channel Activity. Journal of Cardiovascular Pharmacology, 2012, 59, 539-546.	1.9	21
24	Acacetin suppresses the electrocardiographic and arrhythmic manifestations of the J wave syndromes. PLoS ONE, 2020, 15, e0242747.	2.5	20
25	Atria are More Sensitive Than Ventricles to GS-458967-Induced Inhibition of Late Sodium Current. Journal of Cardiovascular Pharmacology and Therapeutics, 2015, 20, 501-508.	2.0	17
26	A temporal window of vulnerability for development of atrial fibrillation with advancing heart failure. European Journal of Heart Failure, 2014, 16, 271-280.	7.1	15
27	Inhibition of IKr potentiates development of atrial-selective INa block leading to effective suppression of atrial fibrillation. Heart Rhythm, 2015, 12, 836-844.	0.7	15
28	How Do Atrial-Selective Drugs Differ From Antiarrhythmic Drugs Currently Used in the Treatment of Atrial Fibrillation, 2008, 1, 98-107.	0.5	15
29	Role of Repolarization Restitution in the Development of Coarse and Fine Atrial Fibrillation in the Isolated Canine Right Atria. Journal of Cardiovascular Electrophysiology, 2005, 16, 639-645.	1.7	12
30	The Small Conductance Calcium-Activated Potassium Channel Inhibitors NS8593 and UCL1684 Prevent the Development of Atrial Fibrillation Through Atrial-Selective Inhibition of Sodium Channel Activity. Journal of Cardiovascular Pharmacology, 2020, 76, 164-172.	1.9	10
31	Investigational Anti–Atrial Fibrillation Pharmacology and Mechanisms by Which Antiarrhythmics Terminate the Arrhythmia: Where Are We in 2020?. Journal of Cardiovascular Pharmacology, 2020, 76, 492-505.	1.9	7
32	Ranolazine versus amiodarone for prevention of postoperative atrial fibrillation. Future Cardiology, 2011, 7, 733-737.	1.2	6
33	Is extensive atrial fibrosis in the setting of heart failure associated with a reduced atrial fibrillation burden?. PACE - Pacing and Clinical Electrophysiology, 2018, 41, 1289-1297.	1.2	6
34	Atrial Fibrillation Induced by Anticancer Drugs and Underling Mechanisms. Journal of Cardiovascular Pharmacology, 2022, 80, 540-546.	1.9	4
35	Depolarization of the atrial resting membrane potential as an approach to enhance the anti–atrial fibrillation efficacy of sodium channel blockers. Heart Rhythm, 2021, 18, 1221-1222.	0.7	2
36	Intracellular uptake of agents that block the hERG channel can confound the assessment of QT interval prolongation and arrhythmic risk. Heart Rhythm, 2021, 18, 2177-2186.	0.7	2

#	Article	IF	CITATIONS
37	Advances in the Pharmacologic Management of Atrial Fibrillation. Cardiac Electrophysiology Clinics, 2011, 3, 157-167.	1.7	0
38	Mechanisms Underlying the Development of Cardiac Arrhythmias. Contemporary Cardiology, 2020, , 33-74.	0.1	0
39	Advances in the Pharmacological Treatment of Atrial Fibrillation. Current Medical Literature Cardiology, 2010, 29, 1-5.	0.0	0